LONDON – Celyad SA bounced back from the phase III failure of its C-Cure stem cell therapy in congestive heart failure to seal a $311.5 million plus royalties deal with Japanese pharma Ono Pharmaceutical Co Ltd., for the development and commercialization of a preclinical-stage allogeneic T-cell immunotherapy.